
    
      This was a randomized, double-blind, parallel group, placebo-controlled, 12-weeks 200 mg
      b.i.d oral dose treatment of AFQ056 (following a 4 week up-titration period and followed by a
      3 week down-titration period) or matched placebo in patients diagnosed with OCD and on
      background SSRI treatment for at least 12 weeks. Study was prematurely terminated at the time
      of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective.
    
  